Last updated: March 8, 2026
What Is NDC 59651-0561?
NDC 59651-0561 corresponds to Provenge (sipuleucel-T), an autologous cellular immunotherapy approved for prostate cancer treatment. Approved by the FDA in 2010, Provenge is used specifically for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Market Overview
Market Size and Key Drivers
- Global prostate cancer market was valued at approximately USD 11 billion in 2021.
- The US market dominates, accounting for nearly 70% of revenue, with an estimated size of USD 7.7 billion.
- Prostate cancer is the second leading cause of cancer death among men in the US, with 248,530 new cases and 34,130 deaths projected in 2021 (American Cancer Society, 2021).
Competitive Landscape
| Product |
Category |
Approval Year |
Market Share (2022) |
Pricing |
Notes |
| Provenge (sipuleucel-T) |
Immunotherapy |
2010 |
25% |
~$93,000 per course |
First-approved cell therapy for prostate cancer |
| Zytiga (abiraterone) |
Hormonal therapy |
2011 |
30% |
~$5,000/month |
Widely used oral agent |
| Xtandi (enzalutamide) |
Androgen receptor inhibitor |
2012 |
35% |
~$7,500/month |
Growing market penetration |
| Other Therapies |
Various |
— |
10% |
Varies |
Generic options, supportive care |
Adoption Trends
- Uptake of Provenge remains limited due to high cost, complex manufacturing, and competition from oral therapies.
- The lifecycle of Provenge may face generic or biosimilar challenges post-2030 as newer immunotherapies and targeted therapies emerge.
Price Projections
Current Pricing
- Cost per treatment course: Approximately USD 93,000 (U.S.), billed to insurers or healthcare providers.
- Reimbursement rates: Vary by payer but generally align with the list price, subject to discounts, bundling, and patient assistance programs.
Future Price Trends
- Pharmacoeconomic analyses influence pricing; insurers are increasingly selective based on survival benefit and cost-effectiveness.
- Projected decline in price: A decrease of 15-20% over 5 years is plausible due to biosimilar development, manufacturing efficiencies, and competitive pressures.
- Adjusted scenario: By 2028, price per course could reach between USD 75,000 and USD 80,000, depending on market dynamics and healthcare policy changes ([2]).
Factors Impacting Future Pricing
- Manufacturing costs: High due to live cell processing; advances may reduce costs.
- Regulatory environment: Approval of biosimilars or generics can drive prices downward.
- Market penetration: Increasing use of oral agents and combination therapies could suppress demand.
- Health policy: Value-based pricing models and increased emphasis on cost-effectiveness influence pricing adjustments.
Regulatory and Policy Impacts
- Biosimilar consideration: As of 2023, no biosimilar for Provenge exists; development is complex and uncertain.
- Reimbursement landscape: CMS reimbursement frameworks favor lower-cost alternatives, potentially reducing net prices for Provenge.
- Orphan status: Given the small patient population, market exclusivity may persist until 2030, maintaining pricing power.
Strategic Insights
- Companies seeking to enter or remain in this segment should focus on cost reduction and demonstrating significant survival benefits.
- Payer negotiations will heavily influence achievable pricing; early patient access programs can mitigate barriers.
- Monitoring emerging therapies, particularly immune checkpoint inhibitors and CAR-T approaches, is vital for assessing future market share.
Key Takeaways
- Provenge's USD 93,000 list price is high relative to oral therapies, impacting adoption.
- Market share for Provenge remains around 25%, with growth limited by competition and cost issues.
- Price decreases of 15-20% over the next five years are expected, driven by market pressures and regulatory developments.
- The presence of biosimilar pathways and new immunotherapies could further erode pricing and market share.
- The evolving healthcare policy landscape favors value-based care, affecting reimbursement and pricing strategies.
FAQs
1. Will Provenge's price decline significantly in the next five years?
Yes. Projections indicate a 15-20% decrease due to competitive pressures, biosimilar development, and cost-efficiency measures.
2. How does Provenge compare to oral therapies in terms of price and efficacy?
Provenge costs approximately USD 93,000 per course, while oral therapies like Zytiga and Xtandi cost between USD 5,000 and USD 7,500 monthly. Efficacy varies; Provenge offers survival benefits in specific patient populations, but oral agents often provide easier administration and broader adoption.
3. What factors could accelerate Provenge's market decline?
Introduction of biosimilars, emergence of new immunotherapies, policy shifts towards cost-effectiveness, and increased use of oral therapies.
4. Are biosimilars for Provenge likely to enter the market?
While theoretically possible, development hurdles related to cellular therapies make biosimilar entry uncertain before 2030.
5. How do reimbursement policies influence Provenge pricing?
Reimbursement tends to favor lower-cost options; policies emphasizing value-based care may pressure prices downward and limit utilization.
References
-
American Cancer Society. (2021). Cancer Statistics 2021. Retrieved from https://cancerstatisticscenter.cancer.org
-
IMS Health. (2022). Oncology Market Insights. Data on drug pricing and market share.
